Deferasirox (Exjade®, ICL670) Preclinical Overview

Seminars in Hematology

Volumn 44, Issue SUPPL. 3, 2007, Pages

  Nick, Hanspeter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE MESYLATE; IRON 59;

ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG TOLERABILITY; IRON BINDING CAPACITY; IRON METABOLISM; IRON OVERLOAD; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 34248531413     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.03.005     Document Type: Article

References (17)

1. Bickel H., Gaeumann E., Keller-Scherlein W., et al. On iron-containing growth factors, sideramines, and their antagonists, the iron-containing antibiotics, sideromycins. Experientia 16 (1960) 129-133
2. Delea T.E., Sofrygin O., Baladi J.F., et al. Costs and consequences of inadequate compliance with deferoxamine therapy in patients with transfusion-dependent thalassemia. Blood 106 11 (2005) 3134 abstr
3. Modell B., Khan M., and Darlison M. Survival in β-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 355 (2000) 2051-2052
4. Acklin P. A molecular-mechanics approach for the prediction of the geometry of high-spin feIII complexes with oxygen and nitrogen as coordinating atoms. Helvetica Chima Acta 83 (2000) 677
5. Nick H., Acklin P., Lattmann R., et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10 (2003) 1065-1076
6. Steinhauser S., Heinz U., Bartholoma M., et al. Complex formation of ICL670 and related ligands with Fe III and Fe II. Eur J Inorg Chem 21 (2004) 4177-4192
7. Sergejew T., Forgiarini P., and Schnebli H.P. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 110 (2000) 985-992
8. Wood J.C., Otto-Duessel M., Gonzales I., et al. ICL670 removes cardiac iron in a gerbil model of iron overload. Blood 106 11 (2005) 2695 abstr
9. Glickstein H., Ben El R., Link G., et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 108 (2006) 3195-3203
10. Hershko C., Konijn A.M., Nick H.P., et al. ICL670A: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97 (2001) 1115-1122
11. Nick H., Wong A., Acklin P., et al. ICL670A: Preclinical profile. Adv Exp Med Biol 509 (2002) 185-203
12. Galanello R., Piga A., Alberti D., et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 43 (2003) 565-572
13. Cappellini M.D., Cohen A., Piga A., et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
14. ®, ICL670) is well tolerated and reduces iron burden. Blood 106 11 (2005) 313 abstr
15. Galanello R., Piga A., Forni G.-L., et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with b-thalassaemia major. Haematologica 91 (2006) 1343-1351
16. ®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
17. Cazzola M., Gattermann N., Greenberg P., et al. ICL670, a once-daily iron chelator, is effective and well tolerated in patients with myelodysplastic syndrome (MDS) and iron overload. Haematologica 90 suppl 2 (2005) 306